BioSpace News Archive

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) today announced that Dr. Stacy Lindborg, Co-Chief Executive Officer, and Chaim Lebovits, President and Chief Executive Officer, will participate in a fireside chat at the Maxim Group Healthcare Virtual Conference on Wednesday, June 21, 2023 at 9:00 a.m. Eastern Time.

TRACON Pharmaceuticals, Inc. announced that Charles Theuer, M.D., Ph.D., President and Chief Executive Officer, will present a corporate overview at the Maxim Group Healthcare Virtual Conference on Tuesday, June 20, 2023 at 3:30 pm Eastern Time.

On June 11, 2023, Viva Biotech Holdings Group announced that Viva Shanghai, the primary entity for Viva Biotech’s CRO business, successfully raised nearly US$ 150 million through the transfer of approximately 24% of its equity interest to Temasek, HLC, and True Light.

Cholesgen Co.Ltd. announced an exciting new collaboration to advance research and development in hypercholesterolemia and related metabolic diseases with AstraZeneca.

Ironwood Pharmaceuticals, Inc. announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, in connection with Ironwood’s pending acquisition of VectivBio, expired at 11:59 p.m., Eastern Time, on June 15, 2023.

Altimmune, Inc. announced that Dr. Scott Harris, Chief Medical Officer at Altimmune, has been invited to participate on a Metabolic panel at the Healthcare Virtual Conference Part II, presented by Maxim Group LLC and hosted by M-Vest, on Tuesday, June 20th, 2023 at 11:00 A.M. ET.

“We care for your samples, you care for science” – Singleron holds true to their slogan as reliable partner to scientists and clinicians.

Verastem Oncology announced the pricing of an underwritten public offering of 7,181,409 shares of its common stock at a price to the public of $9.75 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to an aggregate of 1,538,591 shares of its common stock at a price of $9.749 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant.

Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, presented new non-human primate data supporting the clinical advancement of EPI-321 for the treatment of facioscapulohumeral muscular dystrophy.

Actinium Pharmaceuticals, Inc., a leader in the development of targeted radiotherapies, announced that the Company will participate in a fireside chat at the Maxim Healthcare Virtual Conference on Wednesday, June 21, 2023 at 12:30 PM EST.